Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a...

Keywords

MedicineOxaliplatinCapecitabineFOLFIRINOXChemotherapyTotal mesorectal excisionChemoradiotherapyColorectal cancerIrinotecanFluorouracilEpirubicinNeoadjuvant therapySurgeryFebrile neutropeniaFOLFOXInternal medicineNeutropeniaCancerBreast cancer

Affiliated Institutions

Related Publications

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

Kate Sumpter , Catherine Harper‐Wynne , David Cunningham +9 more

2005 British Journal of Cancer 143 citations

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy , Françoise Desseigne , Marc Ychou +17 more

International audience

2011 New England Journal of Medicine 7440 citations

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors

Marc Ychou , Thierry Conroy , Jean‐François Seitz +4 more

2003 Annals of Oncology 112 citations

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer , Esmée A. Dijkstra , Boudewijn van Etten +97 more

Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And P...

2020 The Lancet Oncology 1432 citations

Publication Info

Year: 2021
Type: article
Volume: 22
Issue: 5
Pages: 702-715
Citations: 1089
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1089

OpenAlex

Cite This

APA Style

                            
                                
                                    Thierry Conroy, 
                                
                                    Jean-François Bosset, 
                                
                                    Pierre-Luc Etienne
                                
                                et al.
                            
                            (2021). 
                            Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. 
                            The Lancet Oncology
                            , 22
                            (5)
                            , 702-715.
                            https://doi.org/10.1016/s1470-2045(21)00079-6
                        

Identifiers

DOI: 10.1016/s1470-2045(21)00079-6